DLHL
CLSD

Donald L. Hagan LLC’s Clearside Biomedical CLSD Stock Holding History

Donald L. Hagan LLC’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-667
Closed -$24K – 83
2020
Q1 		$24K Sell
667
-266
-29% -$9.84K 0.02% 80
2019
Q4 		$40K Buy
+933
New +$19.6K 0.03% 87

Other funds holding CLSD

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Donald L. Hagan LLC's CLSD Position: Q2 2020 in Review

Donald L. Hagan LLC sold out of Clearside Biomedical (CLSD) in Q2 2020, closing a stake of 667 shares — an estimated $24K sold.

Donald L. Hagan LLC first reported a position in CLSD in Q4 2019 and held it in 2 quarters. The position peaked at $40K in Q4 2019. 45 funds tracked by Wall St. Rank hold CLSD as of Q2 2020.

  • Donald L. Hagan LLC reported no remaining Clearside Biomedical position as of Q2 2020 after selling out during the quarter.
  • Donald L. Hagan LLC sold 667 Clearside Biomedical shares in Q2 2020, an estimated $24K.
  • Donald L. Hagan LLC first reported a position in Clearside Biomedical in Q4 2019 and held it in 2 quarters.
  • Donald L. Hagan LLC's Clearside Biomedical position peaked at $40K in Q4 2019.
  • 45 funds tracked by Wall St. Rank held Clearside Biomedical as of Q2 2020.

Based on Donald L. Hagan LLC's 13F filing for Q2 2020, filed 3 Aug 2020.